Triple-negative breast cancer (TNBC) is characterized by the absence of the expression of hormone receptors and human epidermal growth factor receptor 2 (HER2) on the tumor cell surface [2] and accounts for 10–15% of breast cancer cases [3, 4]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.